

DAFTAR PUSTAKA

1. Martinotti G, Santacroce R, Papanti D, Elgharably Y, Prilutskaya M, Corazza O. Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset. *CNS Neurol Disord - Drug Targets*. 2017;16(5).
2. UNODC. What are NPS? [Internet]. 2022 [cited 2022 Jul 5]. Available from: <https://www.unodc.org/LSS/Page/NPS>
3. Pusat Penelitian Data dan Informasi. Data Statistik Penanganan Kasus Narkotika [Internet]. 2022 [cited 2022 Jul 5]. Available from: <https://puslitdatin.bnn.go.id/portfolio/data-statistik-kasus-narkoba/>
4. Quamila A, Savitri T. Cap Gorila, Ganja Sintetis yang Bikin Pemakainya Hidup Seperti Zombie [Internet]. 2021. Available from: <https://hellosehat.com/herbal-alternatif/herbal/efek-bahaya-cap-gorilla-ganja-sintetis/>
5. Wiley JL, Marusich JA, Martin BR, Huffman JW. 1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice. *Drug Alcohol Depend* [Internet]. 2012;123(1–3):148–53. Available from: <http://dx.doi.org/10.1016/j.drugalcdep.2011.11.001>
6. Spaderna M, Addy PH, D'Souza DC. Spicing things up: Synthetic cannabinoids. *Psychopharmacology (Berl)*. 2013;228(4):525–40.
7. Brents LK, Prather PL. The K2/Spice Phenomenon: Emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. *Drug Metab Rev*. 2014;46(1):72–85.
8. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. *Drug Alcohol Depend* [Internet]. 2014;144:12–41. Available from: <http://dx.doi.org/10.1016/j.drugalcdep.2014.08.005>
9. Pusat Penelitian Data dan Informasi BNN. Survei Prevalensi 2018. Jakarta; 2019. 28–41 p.
10. Loeffler G, Delaney E, Hann M. International trends in spice use: Prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids. *Brain Res Bull* [Internet]. 2016;126:8–28. Available from: <http://dx.doi.org/10.1016/j.brainresbull.2016.04.013>
11. Notoatmodjo S. Ilmu Perilaku Kesehatan. Jakarta: Rineka Cipta; 2018. 27 p.

12. Notoatmodjo S. Ilmu Perilaku Kesehatan. Jakarta: Rineka Cipta; 2018. 27–28 p.
13. Arikunto S, Yuliana L. Manajemen Pendidikan. Yogyakarta: Aditya Media; 2008.
14. Alizamar, Cuoto N. Psikologi Persepsi & Desain Informasi; Sebuah Kajian Psikologi dan Prinsip Kognitif untuk kependidikan dan Desain Komunikasi Visual. Yogyakarta: Media Akademi; 2016. 15–16 p.
15. Walgito B. Pengantar Psikologi Umum. 4th ed. Yogyakarta: Andi; 2004. 87–88 p.
16. Walgito B. Pengantar Psikologi Umum. 4th ed. Yogyakarta: Andi; 2004. 90 p.
17. Walgito B. Pengantar Psikologi Umum. 4th ed. Yogyakarta: Andi; 2004. 118–129 p.
18. Notoatmodjo S. Ilmu Perilaku Kesehatan. Jakarta: Rineka Cipta; 2018. 29 p.
19. Notoatmodjo S. Ilmu Perilaku Kesehatan. Jakarta: Rineka Cipta; 2018. 29–30 p.
20. Notoatmodjo S. Ilmu Perilaku Kesehatan. Jakarta: Rineka Cipta; 2018. 30–31 p.
21. UU Nomor 35 Tahun 2009. 2009;3.
22. Pusat Penelitian Data dan Informasi BNN. Survei Prevalensi 2018. Jakarta: Pusat Penelitian Data dan Informasi Badan Narkotika Nasional Republik Indonesia; 2019. 8–11 p.
23. Pusat Penelitian Data dan Informasi BNN. Survei Prevalensi 2018. Jakarta; 2019. 18 p.
24. BNN. Indonesia Drugs Report 2021 [Internet]. Vol. 5, Paper Knowledge . Toward a Media History of Documents. Pusat Penelitian Data dan Informasi Badan Narkotika Nasional Republik Indonesia; 2021. 23–46 p. Available from: <https://ppid.bnn.go.id/konten/unggahan/2020/10/IDR-2021.pdf>
25. M. Castanento, D. Gorelick ND et al. Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. *Drug Alcohol Depend.* 2014;144:12.
26. Spaderna M, Addy PH, D’Souza DC. Spicing things up: Synthetic cannabinoids. *Psychopharmacology (Berl)*. 2013;228(4):525.

27. Cooks T, Davis TK, Hu J, Metheny R, Schwartz M, Gerona R. "Smoking" guns: Questions. *Pediatr Nephrol*. 2016;31(1):61–2.
28. Gottlieb S. Statement from FDA warning about significant health risks of contaminated illegal synthetic cannabinoid products that are being encountered by FDA [Internet]. 2018 [cited 2022 Jul 17]. Available from: <https://www.fda.gov/news-events/press-announcements/statement-fda-warning-about-significant-health-risks-contaminated-illegal-synthetic-cannabinoid#:~:text=The FDA has previously worked,imminent hazard to public safety.>
29. De Luca MA, Castelli MP, Loi B, Porcu A, Martorelli M, Miliano C, et al. Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135. *Neuropharmacology* [Internet]. 2016;105(2016):630–8. Available from: <http://dx.doi.org/10.1016/j.neuropharm.2015.11.017>
30. Pertwee RG. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9-tetrahydrocannabinol, cannabidiol and Δ 9-tetrahydrocannabivarin. *Br J Pharmacol*. 2008;153(2):199–215.
31. Hrubá L, McMahon LR. The cannabinoid agonist HU-210: Pseudo-irreversible discriminative stimulus effects in rhesus monkeys. *Eur J Pharmacol* [Internet]. 2014;727(1):35–42. Available from: <http://dx.doi.org/10.1016/j.ejphar.2014.01.041>
32. De Luca MA, Bimpisidis Z, Melis M, Marti M, Caboni P, Valentini V, et al. Stimulation of in vivo dopamine transmission and intravenous self-administration in rats and mice by JWH-018, a Spice cannabinoid. *Neuropharmacology* [Internet]. 2015;99:705–14. Available from: <http://dx.doi.org/10.1016/j.neuropharm.2015.08.041>
33. Glass M, Dragunow M, Faull RLM. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. *Neuroscience*. 1997;77(2):299–318.
34. Ossato A, Vigolo A, Trapella C, Seri C, Rimondo C, Serpelloni G, et al. JWH-018 impairs sensorimotor functions in mice. *Neuroscience* [Internet]. 2015;300:174–88. Available from: <http://dx.doi.org/10.1016/j.neuroscience.2015.05.021>
35. Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, et al. Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. *ACS Chem Neurosci*. 2016;7(9):1241–54.

36. Irie T, Kikura-Hanajiri R, Usami M, Uchiyama N, Goda Y, Sekino Y. MAM-2201, a synthetic cannabinoid drug of abuse, suppresses the synaptic input to cerebellar Purkinje cells via activation of presynaptic CB1 receptors. *Neuropharmacology* [Internet]. 2015;95(March):479–91. Available from: <http://dx.doi.org/10.1016/j.neuropharm.2015.02.025>
37. Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, et al. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: Identification of novel cannabinoid receptor ligands. *Drug Metab Dispos*. 2012;40(11):2174–84.
38. Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. *Toxicol Appl Pharmacol* [Internet]. 2013;269(2):100–8. Available from: <http://dx.doi.org/10.1016/j.taap.2013.03.012>
39. Chimalakonda K, James L, Radominska-Pandya A, Moran J. Sulfaphenazole and α -Naphthoflavone Attenuate the Metabolism of the Synthetic Cannabinoids JWH-018 and AM2201 Found in K2/Spice. *Drug Metab Lett*. 2014;7(1):34–8.
40. Bileck A, Ferik F, Al-Serori H, Koller VJ, Muqaku B, Haslberger A, et al. Impact of a synthetic cannabinoid (CP-47,497-C8) on protein expression in human cells: evidence for induction of inflammation and DNA damage. *Arch Toxicol*. 2016;90(6):1369–82.
41. Carvalho AF, Reyes BAS, Ramalhosa F, Sousa N, Van Bockstaele EJ. Repeated administration of a synthetic cannabinoid receptor agonist differentially affects cortical and accumbal neuronal morphology in adolescent and adult rats. *Brain Struct Funct*. 2016;221(1):407–19.
42. Couceiro J, Bandarra S, Sultan H, Bell S, Constantino S, Quintas A. Toxicological impact of JWH-018 and its phase I metabolite N-(3-hydroxypentyl) on human cell lines. *Forensic Sci Int* [Internet]. 2016;264:100–5. Available from: <http://dx.doi.org/10.1016/j.forsciint.2016.03.024>
43. Koller VJ, Ferik F, Al-Serori H, Mišić M, Nersesyan A, Auwärter V, et al. Genotoxic properties of representatives of alkylindazoles and aminoalkylindoles which are consumed as synthetic cannabinoids. *Food Chem Toxicol* [Internet]. 2015;80:130–6. Available from: <http://dx.doi.org/10.1016/j.fct.2015.03.004>
44. Koller VJ, Zlabinger GJ, Auwärter V, Fuchs S, Knasmueller S. Toxicological profiles of selected synthetic cannabinoids showing high binding affinities to the cannabinoid receptor subtype CB1. *Arch Toxicol*.

2013;87(7):1287–97.

45. Lewis SEM, Paro R, Borriello L, Simon L, Robinson L, Dincer Z, et al. Long-term use of HU210 adversely affects spermatogenesis in rats by modulating the endocannabinoid system. *Int J Androl*. 2012;35(5):731–40.
46. Grim TW, Wiebelhaus JM, Morales AJ, Negus SS, Lichtman AH. Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice. *Drug Alcohol Depend* [Internet]. 2015;150:31–7. Available from: <http://dx.doi.org/10.1016/j.drugalcdep.2015.01.022>
47. Tai S, Hyatt WS, Gu C, Franks LN, Vasiljevik T, Brents LK, et al. Repeated administration of phytocannabinoid Δ^9 -THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. *Pharmacol Res*. 2015;102:22–32.
48. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol*. 2011;163(7):1344–64.
49. Lafaye G, Karila L, Blecha L, Benyamina A. Cannabis, cannabinoids, and health. *Dialogues Clin Neurosci*. 2017;19(3):309–16.
50. Maguire DR, France CP. Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl. *Eur J Pharmacol* [Internet]. 2016;784:199–206. Available from: <http://dx.doi.org/10.1016/j.ejphar.2016.05.018>
51. Botanas CJ, De La Peña JB, Dela Pena IJ, Tampus R, Kim HJ, Yoon SS, et al. Evaluation of the abuse potential of AM281, a new synthetic cannabinoid CB1 receptor antagonist. *Eur J Pharmacol* [Internet]. 2015;766:135–41. Available from: <http://dx.doi.org/10.1016/j.ejphar.2015.10.004>
52. Abdulrahim D, Bowden-Jones O. Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances. *Neptune* [Internet]. 2015;335. Available from: <http://neptune-clinical-guidance.co.uk/wp-content/uploads/2015/03/NEPTUNE-Guidance-March-2015.pdf>
53. Brents LK, Zimmerman SM, Saffell AR, Prather PL, Fantegrossi WE. Differential drug-drug interactions of the synthetic cannabinoids JWH-018 and JWH-073: Implications for drug abuse liability and pain therapy. *J Pharmacol Exp Ther*. 2013;346(3):350–61.
54. Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to

- Δ 9-THC: Mechanism underlying greater toxicity? *Life Sci* [Internet]. 2014;97(1):45–54. Available from: <http://dx.doi.org/10.1016/j.lfs.2013.09.017>
55. Martinotti G, Santacroce R, Papanti D, Elgharably Y. Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset. *CNS Neurol Disord - Drug Targets*. 2017;16(5):20.
 56. Santacroce R, Corazza O, Martinotti G, Bersani FS, Valeriani G, Giannantonio M Di. Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products. *Hum Psychopharmacol Clin Exp* [Internet]. 2015;30:265–71. Available from: <http://dx.doi.org/10.1097/00019442-200303000-00011> %5Cn<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2676262&tool=pmcentrez&rendertype=abstract> %5Cn<http://dx.doi.org/10.2332/allergolint.O-07-525>
 57. Bassir Nia A, Medrano B, Perkel C, Galynker I, Hurd YL. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. *J Psychopharmacol*. 2016;30(12):1321–30.
 58. Winstock AR, Barratt MJ. Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. *Drug Alcohol Depend* [Internet]. 2013;131(1–3):106–11. Available from: <http://dx.doi.org/10.1016/j.drugalcdep.2012.12.011>
 59. Bilgrei OR. From “herbal highs” to the “heroin of cannabis”: Exploring the evolving discourse on synthetic cannabinoid use in a Norwegian Internet drug forum. *Int J Drug Policy* [Internet]. 2016;29:1–8. Available from: <http://dx.doi.org/10.1016/j.drugpo.2016.01.011>
 60. Winstock A, Lynskey M, Borschmann R, Waldron J. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. *J Psychopharmacol*. 2015;29(6):698–703.
 61. Zaurova M, Hoffman RS, Vlahov D, Manini AF. Clinical Effects of Synthetic Cannabinoid Receptor Agonists Compared with Marijuana in Emergency Department Patients with Acute Drug Overdose. *J Med Toxicol* [Internet]. 2016;12(4):335–40. Available from: <http://dx.doi.org/10.1007/s13181-016-0558-4>
 62. Katz KD, Leonetti AL, Bailey BC, Surmaitis RM, Eustice ER, Kacinko S, et al. Case series of synthetic cannabinoid intoxication from one toxicology center. *West J Emerg Med*. 2016;17(3):290–4.
 63. Sherpa D, Paudel BM, Subedi BH, Chow RD. Synthetic cannabinoids: the

- multi-organ failure and metabolic derangements associated with getting high. *J Community Hosp Intern Med Perspect*. 2015;5(4):27540.
64. Nurmedov S, Metin B, Ekmen S, Noyan O, Yilmaz O, Darcin A, et al. Thalamic and cerebellar gray matter volume reduction in synthetic cannabinoids users. *Eur Addict Res*. 2015;21(6):315–20.
 65. Spaderna M, Addy PH, D’Souza DC. Spicing things up: Synthetic cannabinoids. *Psychopharmacology (Berl)*. 2013;228(4):529.
 66. Martinotti G, Santacrose R, Papanti D, Elgharably Y. Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset. *CNS Neurol Disord - Drug Targets*. 2017;16(5):5.
 67. Calabria B, Degenhardt L, Hall W, Lynskey M. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. *Drug Alcohol Rev*. 2010;29(3):318–30.
 68. Pusat Penelitian Data dan Informasi BNN. *Indonesia Drugs Report 2021*. Jakarta: Pusat Penelitian Data dan Informasi Badan Narkotika Nasional Republik Indonesia; 2021. 10 p.
 69. NIDA. *Drugs, Brain, Behavior: The Science of Addiction*. *Sci Addict* [Internet]. 2020;7(3):1–32. Available from: <https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/drugs-brain>
 70. Kementrian Kesehatan. *Riset Kesehatan Nasional* [Internet]. Pusat Penelitian, Data, dan Informasi Badan Narkotika Nasional Republik Indonesia; 2019. 62–64 p. Available from: http://labdata.litbang.kemkes.go.id/images/download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf
 71. Nainggolan S. *Pengantar Survei Riset Kesehatan Masyarakat*. Cirebon: Nusa Literasi Inspirasi; 2018.
 72. Sugiyono. *METODE PENELITIAN KUANTITATIF, KUALITATIF, DAN R&D*. Bandung: ALFABETA; 2013. 80–85 p.